Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Driehaus Capital Management
BioCentury | Apr 4, 2025
Finance
Isomorphic’s $600M funding among four megarounds: Finance Report
Other nine-digit financings go to Airna, Atsena, Neurona
BioCentury | Aug 9, 2024
Finance
Venture Report: Pair of crossover rounds for precision oncology, peptide biotechs
Plus: Financings for newcos Nilo, Jade, Red Queen
BioCentury | Aug 1, 2024
Finance
Venture Report: venBio closes new $528M fifth fund
Plus: Airna, ReviR, LTZ and Synthetica draw Series A cash, while Outpace, Confo and Healx refill their coffers
BioCentury | May 31, 2024
Finance
Public Equity Report: Insmed, Merus raise combined $1B+ after readouts
Plus: PIPEs help Celcuity, Cargo advance clinical programs
BioCentury | May 3, 2024
Finance
Public equity report: Soleno, Abeona raise capital for late-stage rare disease programs
Plus a $100M PIPE for cancer play Context Therapeutics
BioCentury | Apr 10, 2024
Finance
How Goldman Sachs’ life sciences strategy aims to scale private biotechs
Recent investment in Alterome is one of six since 2022 intended to allow biotechs to reach milestones while staying private longer
BioCentury | Apr 5, 2024
Finance
Venture report: Nine-digit rounds for Obsidian, Alterome, Diagonal
Plus: Neurosterix launches with a potential competitor to the schizophrenia therapy developed by Karuna
BioCentury | Jul 12, 2023
Deals
July 11 Quick Takes: Novartis, BeiGene end TIGIT deal
Plus: MPM’s Crossbow debuts with $80M series A and updates from Septerna, ADC, Kelun-Biotech, Evotec and more
BioCentury | Jun 23, 2023
Deals
June 22 Quick Takes: Spyre launches onto NASDAQ via Aeglea merger
Plus: Tourmaline reverse-merging with Talaris, CAR T shows early efficacy in myasthenia gravis, and updates from AltPep, Solve and Intercept
BioCentury | Oct 14, 2022
Finance
Oct. 13 Quick Takes: Epic $168M round for Glick’s Odyssey
Plus Dice raises $300M on back of data, Liu’s Prime Medicine seeking $1.6B valuation, and updates from VectivBio, CSPC, Relmada and more
Items per page:
1 - 10 of 24